MedTrace Logo

Evaluation of the Safety and Effectiveness of BELKYRA® Inj. for the Treatment of Patients With Submental Fullness Due to Submental Fat: A Postmarketing Surveillance Study in Korea

NCT03691415 · Status: TERMINATED · Type: OBSERVATIONAL · Enrollment: 71

Last updated 2020-12-07

No results posted yet for this study

Summary

The purpose of this PMS study is to evaluate the safety and effectiveness of BELKYRA Inj. used according to the dose specified in the instructions for use, for the treatment of patients with SM fullness due to SMF, through active investigation under routine clinical practice

Conditions

  • Submental Fullness

Interventions

DRUG

BELKYRA Inj.

Patient will be administered BELKYRA Inj. at least once and the interval between treatments not less than 1 month apart.

Sponsors & Collaborators

  • Allergan

    lead INDUSTRY

Principal Investigators

  • Suzanne St. Rose, DVM, MSc, PhD · Allergan

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-09-07
Primary Completion
2020-04-14
Completion
2020-04-14

Countries

  • South Korea

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03691415 on ClinicalTrials.gov